Canadian Non-Interventional Study of Xeljanz in Rheumatoid Arthritis (CANTORAL)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/49540
• EU PAS number:
  EUPAS21413
• Study ID:
  49540
• Official title and acronym:
  Canadian Non-Interventional Study of Xeljanz in Rheumatoid Arthritis (CANTORAL)
• DARWIN EU® study:
  No
• Study countries:
  Canada
• Study description:
  The study will describe the baseline, characteristics of Canadian RA patients initiating tofacitinib in clinical practice and subsequently assessing disease activity, patient reported outcomes, and persistence of response.
• Study status:
  Finalised

Research institution and networks

Institutions

Pfizer

Multiple centres: 50 centres are involved in the study, Adachi Medicine Professional Corp, Hamilton, Canada, Manna Research Inc, Burlington, Canada, Nexus Clinical Research, St John's, Canada, Clinical Research and Arthritis Centre, Windsor, Canada, Oshawa Clinic, Oshawa, Canada, Clinique Medicale Viau, Saint-Leonard, Canada

Networks

JSS Medical Research

Study timelines

Date when funding contract was signed

Planned: 01/07/2017

Actual: 12/07/2017

Study start date

Planned: 15/10/2017

Actual: 31/10/2017

Data analysis start date

Planned: 30/11/2019

Date of final study report

Planned: 30/05/2023

Actual: 09/05/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc

Study protocol

Initial protocol

A3921280_FINAL PROTOCOL V1.1_02OCT2017

Updated protocol

A3921280 Protocol Amendment 4 19Jan2022

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable